Page 2 - Ib Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PRESS RELEASE – INSIDE INFORMATION Following a post-hoc analysis of a Phase 3 trial demonstrating pain relief in patients with severe knee osteoarthritis, Biosenic applied for an international...

PRESS RELEASE Dr Nicco's new Chief Operating Officer (COO) position will give her a broader mandate at BioSenic, where she is currently responsible for R&D programs. Mont-Saint-Guibert, Belgium, January 10, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announces the promotion of Dr Carole Nicco to Chief Operating Officer (COO) in ad

BioSenic signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds Mont-Saint-Guibert, Belgium, January 8, 2024, 6pm CEST – BIOSENIC , the company addressing unmet...

BioSenic signs a new subscription agreement for a maximum of EUR 1.2M in convertible bonds Mont-Saint-Guibert, Belgium, January 8, 2024, 6pm CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the company addressing unmet medical needs in auto-immune diseases and orthopedics, today announces that it has signed a new subscription agreement for a maximum EUR 1.2 million convertible bonds ("CBs") facility, arranged by ABO Securities through its affiliated entity Global Tech Opportunities 15 ("GTO

PRESS RELEASE – INSIDE INFORMATION Biosenic signs term sheet with SPRIM Global Investments (TrialCap fund) for up to USD 8 million debt financing and USD 800,000 equity investment as a first decisive, financing step towards a Phase 3 clinical trial for its ground-breaking auto-immune medication, a first-in-class drug oral arsenic salt. Mont-Saint-Guibert, Belgium, December 6, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious aut